Table 1 Association between pre-chemotherapy CD44+/CD24− tumour cell proportions and ALDH1 positivity and clinicopathologic characteristics of the tumours
CD44+/CD24− tumour cell population | ALDH1 expression of tumour cells | ||||
|---|---|---|---|---|---|
Characteristics | Median (IQR) (%) | P -value a | Negative (no. (%)) | Positive (no. (%)) | P -value b |
cT stage | 0.053 | 0.159 | |||
T1 (2) and T2 (47) | 5 (1–42.5) | 40 (50) | 9 (75) | ||
T3 (30) | 5 (1–22.5) | 28 (35) | 2 (17) | ||
T4 (13) | 45 (5–77.5) | 12 (15) | 1 (8) | ||
cN stage | 0.265 | 1.000 | |||
N0 (12) | 25 (1–63.8) | 11 (14) | 1 (8) | ||
N1–3 (80) | 5 (1–40) | 69 (86) | 11 (92) | ||
cTNM stage | 0.288 | 0.538 | |||
II (41) | 5 (1–35) | 37 (46) | 4 (33) | ||
III (51) | 10 (1–45) | 43 (54) | 8 (67) | ||
Histologic grade | 0.002 | 0.007 | |||
Grade I (7) | 5 (1–50) | 7 (9) | 0(0) | ||
Grade II (45) | 5 (0–15) | 43 (56) | 2 (17) | ||
Grade III (37) | 20 (5–65) | 27 (35) | 10 (83) | ||
Oestrogen receptor | <0.001 | <0.001 | |||
Negative (35) | 20 (5–65) | 24 (30) | 11 (92) | ||
Positive (57) | 5 (0–20) | 56 (70) | 1 (8) | ||
HER2 | 0.134 | 0.746 | |||
Negative (63) | 10 (1–55) | 54 (68) | 9 (75) | ||
Positive (29) | 5 (1–15) | 26 (32) | 3 (25) | ||
Breast cancer subtype | 0.001 | <0.001 | |||
Luminal A (40) | 5 (0–35) | 40 (50) | 0 (0) | ||
Luminal B (16) | 3.5 (0–15) | 15 (19) | 1 (8) | ||
HER2+ (13) | 10 (1.5–20) | 11 (14) | 2 (17) | ||
Basal-like (23) | 45 (15–70) | 14 (17) | 9 (75) | ||
Ki-67 labelling index | 0.064 | 0.020 | |||
⩽20% (44) | 5 (0–35) | 42 (53) | 2 (17) | ||
>20% (48) | 12.5 (2–52.5) | 38 (47) | 10 (83) | ||
P53 staining | 0.124 | 0.856 | |||
Negative (67) | 10 (1–45) | 58 (73) | 9 (75) | ||
Positive (25) | 2 (1–15) | 22 (27) | 3 (25) | ||
